METHYLMALONIC ACIDEMIA

Methylmalonic Acidemia — where the specific gene determines whether vitamin B12 therapy normalizes biochemistry, or whether a lifetime of protein restriction and possible liver transplantation is required.

Whole genome sequencing evaluates all methylmalonic acidemia genes — MUT, MMAA, MMAB, MMACHC, MMADHC — distinguishing B12-responsive from B12-non-responsive forms and determining transplant candidacy.

MUT
MMAA
MMAB
MMACHC

About this condition

Methylmalonic Acidemia

Methylmalonic acidemia (MMA) is a group of autosomal recessive organic acidemias caused by impaired conversion of methylmalonyl-CoA to succinyl-CoA in the propionate catabolic pathway. The most severe form is caused by deficiency of methylmalonyl-CoA mutase (MUT gene, chromosome 6p12.3) — the enzyme that requires adenosylcobalamin (vitamin B12) as a cofactor. Additional genes cause MMA through impaired intracellular B12 metabolism: MMAA, MMAB, and MMACHC (the latter also causes combined MMA and homocystinuria, cobalamin C defect). Combined incidence is approximately 1 in 50,000-100,000 births.

MUT-deficient MMA is classified as mut⁰ (no residual enzyme activity, most severe) or mut⁻ (partial residual activity, less severe). MMAA and MMAB variants impair intracellular B12 processing — these patients respond to pharmacological B12 supplementation (hydroxocobalamin injections), which can substantially improve or normalize methylmalonic acid levels. This B12-responsive vs. non-responsive distinction is the most important management classification in MMA. Acute metabolic crises — precipitated by illness, fasting, or protein catabolism — produce metabolic acidosis, hyperammonemia, encephalopathy, and can be fatal. Chronic complications include progressive renal disease, metabolic stroke, optic nerve atrophy, and pancreatitis.

Liver transplantation provides enzyme replacement for the hepatic metabolic defect in MUT-deficient MMA, reducing (but not eliminating) metabolic crisis risk and improving quality of life. Combined liver-kidney transplantation is performed for patients with established renal failure. Gene therapy and mRNA therapy approaches are in clinical development for MUT-deficient MMA — delivering functional MUT mRNA or gene products to restore enzyme activity. Molecular genotyping determines: B12 responsiveness (MMAA/MMAB → responsive; MUT → generally non-responsive), transplant candidacy and urgency, and gene therapy trial eligibility.

MMAA and MMAB variants cause B12-responsive MMA — hydroxocobalamin injections can dramatically reduce methylmalonic acid levels. This is a treatable condition when correctly diagnosed. MUT variants are generally B12-non-responsive.

Gene locus: MUT (6p12.3), MMAA (4q31.21), MMAB (12q24.11), MMACHC (1p34.1)

B12-responsive MMA (MMAA/MMAB) has dramatically better outcomes than MUT-deficient MMA. Newborn screening detects elevated methylmalonic acid but does not identify the gene — molecular diagnosis determines the treatment path.

B12-responsive vs. non-responsive MMA determines whether simple vitamin supplementation or liver transplantation is the treatment path

MMAA-MMA patients treated with regular hydroxocobalamin injections can achieve near-normal methylmalonic acid levels, substantially reducing metabolic crisis risk and renal disease progression. In contrast, MUT mut⁰ patients do not respond to B12 and require strict protein restriction, emergency metabolic protocols, and consideration of liver transplantation for severe recurrent crises. Newborn screening identifies elevated methylmalonic acid but cannot distinguish these categories — molecular genotyping immediately stratifies the patient into the correct treatment pathway.

mRNA therapy in clinical trials targets MUT-deficient MMA — molecular diagnosis determines eligibility for this transformative approach

Systemic mRNA therapy delivering functional MUT mRNA to hepatocytes is in clinical development for mut⁰ and mut⁻ MMA. This approach aims to restore methylmalonyl-CoA mutase activity without liver transplantation. Clinical trial enrollment requires confirmed MUT pathogenic variants — MMAA or MMAB patients are not candidates because their enzyme is functional (the defect is in B12 processing). Molecular genotyping early in life ensures that MUT-deficient patients are identified for current and emerging gene-specific therapies.

Methylmalonic Acidemia — where the specific gene determines whether vitamin B12 therapy normalizes biochemistry, or whether a lifetime of protein restriction and possible liver transplantation is required.

Methylmalonic Acidemia

B12-responsive MMA (MMAA/MMAB) has dramatically better outcomes than MUT-deficient MMA. Newborn screening detects elevated methylmalonic acid but does not identify the gene — molecular diagnosis determines the treatment path.

B12-responsive vs. non-responsive MMA determines whether simple vitamin supplementation or liver transplantation is the treatment path

mRNA therapy in clinical trials targets MUT-deficient MMA — molecular diagnosis determines eligibility for this transformative approach

Others in Metabolic

One test. A lifetime of answers.